Brawijaya University develops GAD65 Rapid Test Diabetes Screening Kit
Malang, East Java, Indonesia, Nov 25, 2020 - (ACN Newswire) - Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and treatment are determined.
The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).
Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing deterioration in the condition of people suffering from the metabolic disease.
The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.
The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.
As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered).
For further information, please contact:
Prof Dr. Aulanni'am, drh., DES
+62 812-3317-600
Public Relations,
Universitas Brawijaya
www.ub.ac.id
www.prasetya.ub.ac.id
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).
Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing deterioration in the condition of people suffering from the metabolic disease.
The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.
The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.
As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered).
For further information, please contact:
Prof Dr. Aulanni'am, drh., DES
+62 812-3317-600
Public Relations,
Universitas Brawijaya
www.ub.ac.id
www.prasetya.ub.ac.id
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com